Watsons approach ensures that patients not only lose weight but also develop sustainable habits that promote long-term health
doi: 10.1038/s41591-026-04440-4 It is important, as I was at pains to emphasise in relation to the existing evidence base for GLP-1s themselves, not to overstate what phase 2 data of this kind can tell us
Its important that a health professional works with you on your journey
The atherogenicity of Lp(a) is substantially greater than that of LDL on a per-particle basis, and elevated Lp(a) has been established as an independent risk factor for ASCVD, particularly in individuals with high LDL-C
Under the expert guidance of Rosaly Stephens, ARNP-C, we help patients navigate their weight loss journey using GLP-1 receptor agonists like Semaglutide, ensuring that every step is monitored for safety, comfort, and long-term success